Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

LENZ Therapeutics, Inc. - Common Stock (NQ: LENZ )

35.50 +1.18 (+3.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about LENZ Therapeutics, Inc. - Common Stock

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval. 
Via Benzinga
Exposures Product Safety
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application. 
Via Benzinga
Exposures Product Safety
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024
LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a... 
Via Benzinga
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.